CORE-ALI: protocol for a pan-European mixed-methods study to develop a core outcome set for acute lower limb ischaemia Authors: Maram Darwish, Lewis Meecham, Leszek Kukulski, Sabrina L M Zwetsloot, Mario D’Oria, Laura Schönherr, Petar Zlatanovic, Vincent Jongkind, Robert Hinchliffe, Florian K Enzmann, Alexander Croo Published: 2025 ABSTRACT AbstractBackgroundAcute lower limb ischaemia (ALI) is a life- and limb-threatening vascular emergency requiring urgent intervention. Despite advancements in therapeutic strategies, outcome reporting for ALI remains inconsistent, limiting evidence synthesis and guideline development. The CORE-ALI study aims to develop a Core Outcome Set (COS) to standardise outcome reporting and ensure the inclusion of both clinical and patient-centred metrics.MethodsCORE-ALI will use a structured, multi-phase methodology guided by the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the Core Outcome Set-STAndards for Reporting (COS-STAR) guidelines. Phase 1 involves stakeholder engagement through semi-structured interviews with patients, clinicians and policymakers from diverse European healthcare systems. Qualitative data will be analysed using thematic analysis to generate a preliminary list of outcomes. In Phase 2, a multi-round Delphi survey (anticipated two to three rounds) will prioritise and refine outcomes through consensus building, with quantitative data analysed using descriptive and non-parametric statistical methods. Phase 3 will culminate in a consensus meeting to finalise the COS. Multilingual accommodations will ensure inclusivity, and General Data Protection Regulation (GDPR)-compliant platforms will secure data handling.Ethics and disseminationThe study has received ethics approval from the Ethics Committee of the Medical University of Innsbruck (EK Nr: 1082/2025) on 20/05/2025. Additional local ethics approvals are required and will be obtained at all participating sites prior to the initiation of recruitment. The final Core outcome set will be disseminated through peer-reviewed publications, presentations at international conferences and engagement with professional societies and patient organisations.Trial registration numberCOMET initiative (Registration No. 3346). STRENGTHS AND LIMITATIONS OF THIS STUDY This study follows internationally recognised COMET and COS-STAR methodological standards for the development of a core outcome set in acute lower limb ischaemia. This study follows internationally recognised COMET and COS-STAR methodological standards for the development of a core outcome set in acute lower limb ischaemia. The study incorporates perspectives from patients, clinicians, researchers and policymakers across multiple European healthcare systems. The study incorporates perspectives from patients, clinicians, researchers and policymakers across multiple European healthcare systems. Translation and cultural adaptation processes promote inclusivity but may introduce variability in interpretation despite efforts to standardise terminology. Translation and cultural adaptation processes promote inclusivity but may introduce variability in interpretation despite efforts to standardise terminology. Participant recruitment may favour centres with established infrastructure, which could limit representation from under-resourced or underserved populations. Participant recruitment may favour centres with established infrastructure, which could limit representation from under-resourced or underserved populations. Introduction Acute lower limb ischaemia (ALI) is a life-threatening and limb-threatening vascular emergency that requires urgent intervention to restore perfusion and prevent irreversible tissue damage.1 2 Despite advances in therapeutic strategies, ALI continues to be associated with significant morbidity and mortality.1 The management of ALI varies across healthcare systems, encompassing surgical, endovascular and hybrid approaches.35 Furthermore, a variety of different protocols exists regarding diagnostic approaches, treatment strategies, antithrombotic regimen, as well as follow-up algorithms. This variability complicates the synthesis of evidence and limits the development of standardised guidelines, underscoring the need for harmonised outcome reporting. Inconsistent outcome definitions and reporting frameworks also make it challenging for clinicians to determine the most effective treatment strategies, potentially leading to sub-optimal patient care and increased variability in clinical outcomes. Standardising outcome measures is essential to facilitate evidence-based decision-making and improve patient prognosis. Core outcome sets (COS) are standardised sets of outcomes advised to be assessed and reported in all clinical trials and observational studies for a particular condition.6 7 By integrating diverse perspectives, including those of patients and their caregivers, healthcare professionals and researchers, COS ensure that reported outcomes reflect the priorities of all stakeholders.7 Furthermore, COS play a pivotal role in improving the comparability of studies, enabling meaningful meta-analyses and facilitating development of evidence-based guidelines.7 8 Despite efforts to standardise outcome reporting in vascular surgery (eg, abdominal aortic aneurysm9 and diabetic foot ulcer10 COS), ALI lacks a dedicated COS. A recent systematic review highlighted inconsistencies in ALI outcome reporting, with a focus on clinical endpoints while neglecting patient-centred metrics.11 Also, the PROMOTE-ALI study, a large multicentre European cohort, revealed significant variability in key outcomes such as amputation-free survival and reintervention rates.3 These findings underscore two major gaps in ALI research: The need to include both clinical and patient-centred outcomes to ensure comprehensive assessment. The need to include both clinical and patient-centred outcomes to ensure comprehensive assessment. The necessity of standardised outcome definitions, including timing of outcome assessment, to facilitate meaningful comparisons across studies and improve the evidence base for ALI treatment. The necessity of standardised outcome definitions, including timing of outcome assessment, to facilitate meaningful comparisons across studies and improve the evidence base for ALI treatment. The CORE-ALI study aims to address these gaps by developing a pan-European COS through a structured, multi-phase methodology. Methodology Objectives This study aims to: Identify key clinical and patient-centred outcomes for ALI. Identify key clinical and patient-centred outcomes for ALI. Develop a COS for ALI. Develop a COS for ALI. Facilitate standardisation in outcome reporting. Facilitate standardisation in outcome reporting. Enhance the evidence base for ALI management. Enhance the evidence base for ALI management. Study design This study is designed to develop a COS for ALI using a structured, multi-phase methodology guided by the principles of the COMET initiative7 and adhering to the COS-STAR reporting standards.8 The study was prospectively registered in the COMET database under registration number #3346.12 The study will consist of three sequential phases: Stakeholder Engagement The study will engage diverse stakeholders, including patients, healthcare professionals and policymakers. The interviews will explore outcome priorities across clinical and patient domains (full breakdown of stakeholder groups in Section 2.3, Participants) Delphi Process A multi-round Delphi survey will be used to achieve consensus on the most critical outcomes. Stakeholders will rate the importance of each outcome, with iterative rounds refining priorities and fostering agreement. Consensus Meeting A final consensus meeting will be held with an international multidisciplinary panel to review unresolved outcomes, validate the COS and ensure its relevance and usability for clinical trials, registries and guidelines. To ensure methodological rigour and address potential issues at critical decision points, two steering group meetings will take place: Pre-Delphi Steering Group Meeting: Pre-Delphi Steering Group Meeting: Before initiating the Delphi survey, a steering group comprising internationally recognised experts in vascular surgery, guideline development and outcome standardisation will convene to review the preliminary outcome list. This group includes senior vascular surgeons, past and present leaders within major vascular societies, and contributors to international clinical guidelines. The steering group will refine definitions, address ambiguities and finalise the survey structure to enhance the robustness of subsequent Delphi rounds. Pre-Consensus Steering Group Meeting: Pre-Consensus Steering Group Meeting: Prior to the final consensus meeting, the steering group will reconvene to review unresolved outcomes from the Delphi process. Only relevant and methodologically robust outcomes will proceed to structured discussion and voting. The agenda and key discussion points for the final consensus meeting will also be refined at this stage. Participants and setting The study will be conducted across multiple European countries, leveraging the extensive network of the European Vascular Research Collaborative (EVRC)13 to capture insights from varied healthcare systems and cultural contexts. To facilitate effective patient recruitment and Delphi study coordination, a local coordinator fluent in the native language will be appointed in each participating country. These coordinators will oversee local study implementation, assist with participant engagement and ensure that data collection aligns with the study protocol. As this study aims to develop a COS through qualitative enquiry and consensus-based methodology, formal power calculations are not applicable. Sample sizes for the qualitative and Delphi phases are guided by principles of thematic saturation and established COS development practice rather than statistical hypothesis testing. Participants The study will include the following key stakeholder groups: Patients and caregiversAdults (≥18 years) diagnosed with ALI within the past 12 months.Patients with varied clinical experiences (eg, limb salvage, amputation and revascularisation).Close caregivers or family members of ALI patients to capture the impact on quality of life and caregiving burdens.Participants must be able to provide informed consent and take part in virtual or in-person interviews.Target Recruitment: 4–10 patients per site, acknowledging variability in participation rates. This range is informed by qualitative research principles, where thematic saturation is typically achieved within 12–20 interviews.14 The final number of participants will be guided by thematic saturation, ensuring comprehensive coverage of key themes while avoiding redundancy. Patients and caregivers Adults (≥18 years) diagnosed with ALI within the past 12 months. Adults (≥18 years) diagnosed with ALI within the past 12 months. Patients with varied clinical experiences (eg, limb salvage, amputation and revascularisation). Patients with varied clinical experiences (eg, limb salvage, amputation and revascularisation). Close caregivers or family members of ALI patients to capture the impact on quality of life and caregiving burdens. Close caregivers or family members of ALI patients to capture the impact on quality of life and caregiving burdens. Participants must be able to provide informed consent and take part in virtual or in-person interviews. Participants must be able to provide informed consent and take part in virtual or in-person interviews. Target Recruitment: 4–10 patients per site, acknowledging variability in participation rates. This range is informed by qualitative research principles, where thematic saturation is typically achieved within 12–20 interviews.14 The final number of participants will be guided by thematic saturation, ensuring comprehensive coverage of key themes while avoiding redundancy. Target Recruitment: 4–10 patients per site, acknowledging variability in participation rates. This range is informed by qualitative research principles, where thematic saturation is typically achieved within 12–20 interviews.14 The final number of participants will be guided by thematic saturation, ensuring comprehensive coverage of key themes while avoiding redundancy. Healthcare professionalsClinicians with at least 2 years of experience managing ALI, including:Vascular surgeonsInterventional radiologistsVascular medicine specialistsNurses specialising in vascular care or rehabilitationGeneral practitionersRehabilitation specialists Healthcare professionals Clinicians with at least 2 years of experience managing ALI, including:Vascular surgeonsInterventional radiologistsVascular medicine specialistsNurses specialising in vascular care or rehabilitationGeneral practitionersRehabilitation specialists Clinicians with at least 2 years of experience managing ALI, including: Vascular surgeons Vascular surgeons Interventional radiologists Interventional radiologists Vascular medicine specialists Vascular medicine specialists Nurses specialising in vascular care or rehabilitation Nurses specialising in vascular care or rehabilitation General practitioners General practitioners Rehabilitation specialists Rehabilitation specialists Policymakers, researchers and service providersIndividuals influencing vascular care policy, including guideline developers, healthcare administrators and national and international health representatives.Experts involved in clinical research, outcome reporting and COS development for ALI.Patient advocacy and support group representatives to ensure patient-centred perspectives are incorporated. Policymakers, researchers and service providers Individuals influencing vascular care policy, including guideline developers, healthcare administrators and national and international health representatives. Individuals influencing vascular care policy, including guideline developers, healthcare administrators and national and international health representatives. Experts involved in clinical research, outcome reporting and COS development for ALI. Experts involved in clinical research, outcome reporting and COS development for ALI. Patient advocacy and support group representatives to ensure patient-centred perspectives are incorporated. Patient advocacy and support group representatives to ensure patient-centred perspectives are incorporated. Setting The study will be conducted virtually using GDPR15-compliant platforms, such as Microsoft Teams for interviews and consensus activities. Recruitment will occur through EVRC-affiliated vascular centres, ensuring geographical and demographic diversity. While this approach facilitates broad engagement, it may introduce selection bias by favouring centres with established research infrastructure. To mitigate this, we will actively seek diverse patient demographics, including participants from rural and underserved communities, through targeted recruitment efforts and collaboration with local patient advocacy groups. The recruiting centres will facilitate the engagement of patients, clinicians and policymakers from countries across Europe, capturing the full range of clinical practices and patient experiences. Study procedures The CORE-ALI study will follow a structured, three-phase process to develop the COS for ALI. Phase 1: Stakeholder engagement The first phase will involve semi-structured qualitative interviews with patients, clinicians and policymakers across at least four European countries, ensuring representation from Northern, Southern, Eastern and Western Europe to capture diverse healthcare system perspectives. Data Collection Data Collection Interviews will be conducted virtually using Microsoft Teams or in person where feasible, ensuring accessibility for all participants. An interview guide informed by the findings of the systematic review on COS for ALI11 and PROMOTE ALI3 will be used to ensure consistency across interviews. Interviews will be conducted in participants’ native languages whenever possible. Local coordinators fluent in the respective languages will facilitate these interviews, and transcripts will be professionally translated into English for analysis. Recruitment and Sampling Recruitment and Sampling Participants will be recruited through EVRC-affiliated centres using purposive random sampling technique to ensure diversity in patient experiences (eg, limb salvage and amputation) and clinical practices. Recruitment materials will be translated into the primary languages of participating countries to enhance inclusivity. Data Analysis Data Analysis Interview transcripts will undergo thematic analysis to identify recurring outcome themes. Framework analysis will further categorise outcomes into clinical, patient-reported and adverse event domains. NVivo software16 will be used to facilitate coding and data organisation. Output Output A preliminary list of outcomes, mapped to the COMET taxonomy, will be synthesised from the results of the interviews and integrated with findings from the systematic review11 and PROMOTE ALI.3 Phase 2: Delphi process In the second phase, a multi-round Delphi survey will refine and prioritise outcomes identified in Phase 1. Stakeholders from across Europe will participate to achieve consensus on the most critical outcomes. Survey Design Survey Design The Delphi survey will be hosted on a secure online platform, with participants rating each outcome’s importance on a 9-point Likert scale (1=not important, 9=critically important). Outcomes will be presented with clear definitions and explanations, supplemented by visual aids if necessary. We anticipate recruiting approximately 50–100 stakeholders, including clinicians, researchers, policymakers and patient representatives, ensuring a balanced and comprehensive perspective. This sample size is based on previous Delphi studies in vascular research and COS9 10 development, where engagement from a diverse range of experts has been shown to achieve robust consensus while maintaining feasibility. Consensus Criteria: Consensus Criteria: Round 1: Inclusion: Outcomes rated 7–9 by ≥70% of participants and 1–3 by ≤15%. Inclusion: Outcomes rated 7–9 by ≥70% of participants and 1–3 by ≤15%. Exclusion: Outcomes rated 1–3 by ≥70% and 7–9 by ≤15%. Exclusion: Outcomes rated 1–3 by ≥70% and 7–9 by ≤15%. No consensus: Outcomes not meeting these thresholds will proceed to Round 2. No consensus: Outcomes not meeting these thresholds will proceed to Round 2. Round 2: Inclusion: Outcomes rated 7–9 by ≥80% of participants. Inclusion: Outcomes rated 7–9 by ≥80% of participants. Exclusion: Outcomes rated 1–3 by ≥80%. Exclusion: Outcomes rated 1–3 by ≥80%. No consensus: Outcomes not meeting inclusion/exclusion thresholds will proceed to No consensus: Outcomes not meeting inclusion/exclusion thresholds will proceed to either: Third Delphi round if >30% of outcomes remain unresolved after Round 2. Third Delphi round if >30% of outcomes remain unresolved after Round 2. Direct discussion at the final consensus meeting if the unresolved outcomes are fewer than 30% of the total list, ensuring feasibility of structured deliberation. Direct discussion at the final consensus meeting if the unresolved outcomes are fewer than 30% of the total list, ensuring feasibility of structured deliberation. Feedback Mechanism: Feedback Mechanism: third Delphi round if>30% of outcomes remain unresolved after Round 2. Direct discussion at the final consensus meeting if the unresolved outcomes are fewer than 30% of the total list, ensuring feasibility of structured deliberation. After each round, participants will receive anonymised group feedback, including median scores and IQRs, to inform their subsequent ratings. To enhance the comprehensiveness of the COS, participants will have the opportunity to suggest additional outcomes they believe are missing from the longlist during the first Delphi round. These suggestions will be reviewed by the study team and, if deemed relevant, incorporated into subsequent Delphi rounds for evaluation. Additionally, an open-comments section will allow stakeholders to justify their ratings or provide context on why certain outcomes should be reconsidered. Phase 3: Consensus meeting The final phase will validate the COS through a structured consensus meeting involving an international multidisciplinary panel of experts. To ensure a structured and efficient consensus process, the consensus meeting will be conducted exclusively with healthcare professionals, policymakers and researchers. Experts will be recruited through the EVRC network and key vascular research groups, ensuring representation from at least four to six countries. The meeting will include approximately 15–25 participants, with a balanced mix of vascular surgeons, interventional radiologists, vascular medicine specialists, researchers with expertise in COS development and policymakers involved in vascular care guidelines development. Participation will be by invitation, prioritising individuals with substantial expertise in ALI care and outcome standardisation. Meeting Format Meeting Format Conducted virtually via Microsoft Teams, the meeting will be facilitated by independent moderators with expertise in consensus methodologies and vascular research. Moderators will be suggested by the steering committee, in consultation with key individuals from the ESVS guideline committees and related expert panels, as well as the EVRC, to ensure neutrality and balanced contributions from all stakeholders. Discussion and Voting Discussion and Voting Outcomes that fail to achieve consensus during the Delphi process will be reviewed in detail. Participants will engage in structured group discussions, followed by anonymous voting tools. An inclusion threshold of ≥75% agreement will be applied. Output Output The finalised COS will categorise outcomes into clinical, patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs), and adverse event domains, with defined time points for measurement. The multi-phase approach of the CORE-ALI study is summarised in figure 1. The CORE-ALI study outline. ALI, acute lower limb ischaemia. Patient and public involvement Patients and members of the public were involved in the development of the interview guides and will participate in the Delphi survey and COS prioritisation. Translation and multilingual accommodation The CORE-ALI study emphasises inclusivity and accessibility as core principles in its pan-European approach. Recognising the linguistic and cultural diversity of participating countries, the study will implement a comprehensive translation strategy to ensure that all stakeholders can meaningfully engage with its processes and materials. To facilitate broad participation, all participant-facing documents, including interview guides, Delphi surveys, consent forms and information sheets, will be translated into the primary languages of each participating country. A forward and backward translation process will be employed to ensure both linguistic accuracy and conceptual clarity. Native-speaking researchers will translate materials into their respective languages, and an independent team will retranslate these documents back into English to confirm that the original meaning has been preserved. To further enhance cultural sensitivity, native-speaking collaborators from each country will review the translated materials, ensuring that terminology and phrasing are contextually appropriate, culturally sensitive and free from potential biases. Additionally, each outcome will be accompanied by a layperson-friendly description to ensure clarity for patient participants. These descriptions will be developed in collaboration with patient representatives and reviewed by both clinicians and linguists to ensure accuracy, accessibility and relevance. Efforts will also be made to standardise terminology across all translated documents, maintaining consistency in the presentation and understanding of key concepts throughout the study phases. For qualitative data, multilingual researchers from the EVRC network will assist with the transcription and coding of non-English interviews. Their expertise will ensure the accurate and culturally informed analysis of data from diverse linguistic groups. Additionally, the finalised COS will be translated into multiple languages to facilitate its dissemination and adoption across Europe, enabling the COS to benefit the widest possible audience. Statistical analysis plan Phase 1: Stakeholder Engagement (Qualitative Analysis) Data collected through semi-structured interviews with stakeholders will undergo a qualitative analysis. Transcripts will be produced verbatim and analysed using a combination of thematic and framework analysis. Outcomes will be categorised into clinical, PROMs and PREMs, and adverse event domains, creating a structured and comprehensive preliminary list for subsequent phases of the study. The analysis will be facilitated by NVivo software.16 Descriptive statistics, such as frequencies and percentages, will be employed to summarise participant demographics and characteristics. Phase 2: Delphi Process (Quantitative Analysis) Quantitative analysis will involve descriptive statistics and non-parametric tests, including Wilcoxon signed-rank tests for comparisons across Delphi rounds. Consensus thresholds are predefined (as detailed in Section 2.4: Study procedures). Graphical visualisations (boxplots, histograms) will highlight trends in outcome ratings. Data analysis for the Delphi process will be conducted using SPSS or R software. Phase 3: Consensus Meeting (Quantitative and Qualitative Integration) The final phase will integrate quantitative and qualitative analyses to validate the COS. Outcomes that achieve consensus during the Delphi process will undergo a final review, while those failing to meet inclusion thresholds will be revisited during structured discussions. Voting during the consensus meeting will be conducted anonymously using electronic tools, such as Mentimeter, to ensure unbiased contributions. The inclusion of outcomes in the final COS will require agreement from at least 75% of participants. Results from the voting process will be quantitatively analysed to confirm inclusion thresholds, and unresolved outcomes will be qualitatively reviewed to explore the rationale for disagreement. Thematic analysis of discussion transcripts will document stakeholder perspectives and provide justification for the final decisions. Anticipated challenges and contingency measures The CORE-ALI study recognises several potential challenges that may arise during the statistical analysis and consensus-building process and outlines proactive strategies to address them. One key concern is the possibility of low-response rates during the Delphi survey rounds, which could affect the representativeness of the findings. To mitigate this, survey deadlines will be extended where necessary, and personalised reminders will be issued to participants to encourage timely completion. Interim analyses will be conducted to identify patterns in non-responses or barriers to participation, allowing for targeted interventions to re-engage stakeholders effectively. Achieving consensus on key outcomes can also present a challenge, particularly when stakeholder opinions diverge significantly. To address this, in-depth discussions will be facilitated during the consensus meeting, drawing on qualitative insights from the earlier stakeholder engagement phase to provide context and clarify disagreements. For persistent disagreements, iterative voting rounds will be employed, allowing participants to reassess their positions based on anonymised group feedback and detailed discussions. Technical or data processing issues, such as server failures or software-related problems, represent another potential risk. To ensure data integrity and continuity, backup copies of all data will be maintained on secure servers, and technical support will be readily available to address any issues that arise during data collection or analysis. Additionally, clear guidance and training on the use of virtual tools and platforms, such as Redcap, CASTOR, Microsoft Teams and Mentimeter, will be provided to participants and research team members. Ethics and dissemination Ethics The CORE-ALI study has received approval from the Ethics Committee of the Medical University of Innsbruck (Reference: EK Nr: 1082/2025) on 20/05/2025, which serves as the coordinating centre. Additional local ethics approvals have been obtained or are in progress at participating sites across Europe, in accordance with national and institutional requirements. All participating centres, including those joining the study at a later stage, will be required to obtain local ethics approval prior to commencing recruitment. An overview of ethics approvals secured to date is provided in online supplemental table 1. All participants will provide written informed consent, with digital consent options available for those participating remotely. Data confidentiality will be maintained through pseudonymisation, and all data will be stored securely on General Data Protection Regulation (GDPR)–compliant platforms (eg, REDCap, CASTOR). Access to identifiable data will be restricted to authorised study personnel only. Dissemination The findings of the CORE-ALI study will be disseminated through a combination of academic and public channels to maximise its impact. The finalised COS will be published in peer-reviewed journals. Additionally, results will be presented at major international vascular surgery conferences to reach a broad audience of clinicians, researchers and policymakers. Discussion The CORE-ALI study has the potential to represent a significant advancement in the development of standardised outcome reporting for ALI. By building on foundational work, this protocol addresses critical gaps in current practices. No previous ALI COS framework has been developed, but other initiatives like a Delphi consensus on registry data and a systematic review on outcome reporting in ALI have paved the way for the current initiative. Importantly, CORE-ALI addresses the urgently needed integration of patient-centred perspectives and comprehensive stakeholder engagement. Our study will take an inclusive and methodologically robust approach (which has already been successfully applied in other vascular domains10 17 18, leveraging a pan-European scope and ensuring the involvement of patients, healthcare providers (HCP), and policymakers and researchers from diverse countries and healthcare settings. CORE-ALI aims to optimise this process by focusing on linguistic and cultural inclusivity. By employing a translation and multilingual accommodation process, the protocol ensures accessibility and relevance across Europe’s diverse populations. Additionally, the use of semi-structured interviews to engage stakeholders will directly allow for the identification of outcomes that are meaningful not only to clinicians and researchers but also to the patients most affected by ALI. The methodological strengths of this study lie in its international, multidisciplinary and inclusive design, ensuring broad representation of stakeholders from diverse healthcare systems and cultural contexts across Europe. By integrating perspectives from vascular surgeons, interventional radiologists, policymakers, rehabilitation specialists and patients, the study captures a comprehensive range of priorities for ALI care. The use of GDPR-compliant platforms for data collection and management further underscores the study’s commitment to methodological rigour and data security. Despite its strengths, the study acknowledges certain limitations. Recruitment across multiple European countries may pose logistical challenges, particularly in ensuring equitable representation of underrepresented groups. However, the extensive network of the EVRC and the targeted use of purposive random sampling aims to mitigate these risks. Additionally, the Delphi consensus process inherently carries risks of selection bias, as participants are often self-selected and assessment bias, where stakeholder perspectives may be influenced by prior experiences or dominant voices in the field. To minimise these risks, we will ensure diverse stakeholder representation across geographical, professional and patient demographics and implement structured anonymised voting in the Delphi process. Similarly, the reliance on virtual tools, while enabling broader participation, may present technical challenges for some stakeholders. Clear guidance and technical support will be provided to minimise these barriers. The anticipated impact of the CORE-ALI study also extends beyond ALI management. The development of a standardised COS has the potential to improve the comparability of clinical trials and registries, enhance evidence synthesis and support the creation of better evidence-based guidelines for ALI management. Furthermore, the detailed study’s methodology serves as a replicable framework for COS development in other vascular conditions, contributing to the broader advancement of outcome standardisation in vascular surgery. Furthermore, public engagement will be fostered through collaboration with patient advocacy groups and healthcare organisations, ensuring that the COS is not only adopted in research but also incorporated into clinical practice guidelines. Open-access publication will be prioritised to facilitate widespread dissemination. Timelines and project status Ethical approvals are anticipated to be concluded by the second quarter of 2025, with Phase 1 (Stakeholder Engagement) starting in the third quarter of 2025. Phase 2 (Delphi Process) is expected to commence in the first quarter of 2026, followed by the consensus meeting in the second quarter of 2026. The finalised COS is projected to be ready by the end of 2026, with dissemination and reporting planned for the first half of 2027. Supplementary material